1. Home
  2. EYPT vs XNET Comparison

EYPT vs XNET Comparison

Compare EYPT & XNET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EYPT
  • XNET
  • Stock Information
  • Founded
  • EYPT 1987
  • XNET 2003
  • Country
  • EYPT United States
  • XNET China
  • Employees
  • EYPT N/A
  • XNET N/A
  • Industry
  • EYPT Biotechnology: Laboratory Analytical Instruments
  • XNET Computer Software: Prepackaged Software
  • Sector
  • EYPT Industrials
  • XNET Technology
  • Exchange
  • EYPT Nasdaq
  • XNET Nasdaq
  • Market Cap
  • EYPT 390.0M
  • XNET 276.3M
  • IPO Year
  • EYPT 2005
  • XNET 2014
  • Fundamental
  • Price
  • EYPT $5.94
  • XNET $4.49
  • Analyst Decision
  • EYPT Strong Buy
  • XNET
  • Analyst Count
  • EYPT 7
  • XNET 0
  • Target Price
  • EYPT $24.00
  • XNET N/A
  • AVG Volume (30 Days)
  • EYPT 685.1K
  • XNET 384.1K
  • Earning Date
  • EYPT 05-07-2025
  • XNET 05-15-2025
  • Dividend Yield
  • EYPT N/A
  • XNET N/A
  • EPS Growth
  • EYPT N/A
  • XNET N/A
  • EPS
  • EYPT N/A
  • XNET 0.02
  • Revenue
  • EYPT $56,042,000.00
  • XNET $323,140,000.00
  • Revenue This Year
  • EYPT N/A
  • XNET N/A
  • Revenue Next Year
  • EYPT N/A
  • XNET N/A
  • P/E Ratio
  • EYPT N/A
  • XNET $226.84
  • Revenue Growth
  • EYPT 12.04
  • XNET N/A
  • 52 Week Low
  • EYPT $3.91
  • XNET $1.46
  • 52 Week High
  • EYPT $21.26
  • XNET $5.52
  • Technical
  • Relative Strength Index (RSI)
  • EYPT 48.48
  • XNET 59.27
  • Support Level
  • EYPT $5.75
  • XNET $4.25
  • Resistance Level
  • EYPT $7.45
  • XNET $4.54
  • Average True Range (ATR)
  • EYPT 0.47
  • XNET 0.22
  • MACD
  • EYPT -0.05
  • XNET 0.07
  • Stochastic Oscillator
  • EYPT 22.35
  • XNET 86.85

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

About XNET Xunlei Limited

Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.

Share on Social Networks: